The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE
Status:
Completed
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
The COMBINE clinical trial is a pilot study evaluating the effects of nicotinamide and
lanthanum carbonate on serum phosphate and fibroblast growth factor 23 (FGF23) in patients
with Chronic Kidney Disease (CKD) stages 3-4.
Phase:
Phase 2
Details
Lead Sponsor:
John Kusek The Cleveland Clinic
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)